AAV-delivered pancreatic gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones (GLP-1, GIP, PYY, amylin, glucagon). Modular platform using AAV9 vectors with tissue-restricted insulin promoter-driven transgene expression, delivered via proprietary endoscopic device directly to the pancreas.

Targets: GLP-1, GIP, PYY, amylin

Discontinued (1)

Revita — Type 2 Diabetes · Strategic Reprioritization announced January 31, 2025; investment in Revita for T2D paused including REVITALIZE-1 study

Biotech Distilled coverage (5)

2026-05-12 UPDATE: Fractyl Health (GUTS) - The Moonshot Gets a Clinic 🔒 Paid
2026-03-29 UPDATES: Fractyl Health (GUTS) - Insiders Buys 🔒 Paid
2026-02-28 UPDATE: Fractyl Health (GUTS) - The Clock is Set 🔒 Paid
2026-01-30 UPDATE: Fractyl Health (GUTS) - The Mixed Data Crash (6-Mo Readout) 🔒 Paid
2026-01-07 Fractyl Health (GUTS): Scientific Deep Dive for Revita® and Rejuva®

Articles open on Substack. Some deep dives are subscriber-only.